Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing preclinical mechanisms and clinical trial findings without systematic review methodology.
PubMed 39940712 · doi:10.3390/ijms26030944
What was done
The authors conducted a narrative review synthesizing current knowledge regarding the molecular structure, mechanisms of action, preclinical findings, and clinical trial evidence (including PROGRESS-HF, TAZPOWER, MMPOWER-3, and ReCLAIM) for the mitochondria-targeted tetrapeptide elamipretide (SS-31, MTP-131, Bendavia).
What was found
The abstract provides a qualitative summary without quantitative metrics. Mechanistically, elamipretide selectively binds cardiolipin in the inner mitochondrial membrane, stabilizing cristae architecture, lowering oxidative stress, and increasing adenosine triphosphate (ATP) production. Preclinical and clinical investigations report therapeutic activity across heart failure, neurodegenerative disorders, ischemia-reperfusion injury, metabolic syndromes, and muscle weakness.
Why it matters
Elamipretide represents a direct approach to targeting mitochondrial membrane lipid structure and bioenergetic dysfunction, which are common pathways in diverse cardiovascular, neuromuscular, and metabolic diseases.
Limits
The abstract reports no quantitative outcome data, effect estimates, or statistical pooling. As a narrative review, it lacks systematic search criteria, quality appraisal of included studies, and risk of bias assessments. Details regarding sample sizes, clinical endpoints, safety profiles, and long-term efficacy across the cited trials are not detailed in the abstract.
Cited by
- supports SS-31 (elamipretide) provides mitochondrial support.